PulseSight Therapeutics SAS announced that the first patient has been successfully dosed in its phase 1 clinical trial aiming to assess the safety and tolerability of its lead program, PST-611, in humans.

PST-611 is a first-in-class, non-viral vectorized therapy for the treatment of dry age-related macular degeneration (AMD) and geographic atrophy (GA). It expresses human transferrin, a potent iron regulator that plays a central role in restoring normal iron homeostasis, the company said in a press release.

According to PulseSight, the first-in-human single ascending dose trial will include between 6 and 12 patients with dry AMD or GA. It is intended to support a subsequent phase 2a proof-of-concept trial. Preliminary results are expected in early 2026, pending patient recruitment, the company said.

The study is being conducted by Professor Francine Behar-Cohen, MD, PhD, the inventor of the technology, at Cochin Hospital in Paris, and Professor Christophe Chiquet, MD, PhD, at Grenoble Alpes University Hospital in Grenoble, France. RP